CytomX Therapeutics CTMX Payments to Acquire Short-Term Investments
Payments to Acquire Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's payments to acquire short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's payments to acquire short-term investments?
- CytomX Therapeutics (CTMX) reported payments to acquire short-term investments of $242.78M in Q1 2026.
- How has CytomX Therapeutics's payments to acquire short-term investments changed year-over-year?
- CytomX Therapeutics's payments to acquire short-term investments increased by 1127.1% year-over-year, from $19.79M to $242.78M.
- What is the long-term trend for CytomX Therapeutics's payments to acquire short-term investments?
- Over 4 years (2021 to 2025), CytomX Therapeutics's payments to acquire short-term investments has grown at a 17.8% compound annual growth rate (CAGR), from $99.9M to $192.52M.